Photo of Michael G. Muto,  MD

Michael G. Muto, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-8840
Fax: (617) 738-5124


mmuto@partners.org

Michael G. Muto, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Associate Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Director, Gynecologic Oncology Fellowship Program, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Muto has a special research interest in ovarian cancer occurring in women with a genetic predisposition to the disease. He is Co-Director of the Familial Ovarian Cancer Center in the Cancer Risk and Prevention Service at the Dana-Farber Cancer Institute. In this capacity, he is involved in the clinical management of women with BRCA-1 and BRCA-2 mutations. He is interested in chemoprevention, the efficacy of ultrasound, and CA-125 in early detection and in the role of prophylactic surgery in the prevention of ovarian cancer in these high risk women. His clinical activity supports molecular biologic studies in the etiology of papillary serous carcinoma of the peritoneum, a disease which may occur following prophylactic surgery and which has an impact upon the effectiveness of the operation.

Publications

Powered by Harvard Catalyst
  • Aviki EM, Esselen KM, Barcia SM, Nucci MR, Horowitz NS, Feltmate CM, Berkowitz RS, Orgill DG, Viswanathan AN, Muto MG. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol 2015; 137:60-5. PubMed
  • George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer 2014. PubMed
  • Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol 2014. PubMed
  • Oduyebo T, Rauh-Hain AJ, Meserve EE, Seidman MA, Hinchcliff E, George S, Quade B, Nucci MR, Del Carmen MG, Muto MG. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol 2014; 132:360-5. PubMed
  • Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol 2014; 132:55-60. PubMed
  • Barroilhet L, Vitonis A, Shipp T, Muto M, Benacerraf B. Sonographic predictors of ovarian malignancy. J Clin Ultrasound 2013; 41:269-74. PubMed
  • Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol 2013; 129:69-73. PubMed
  • Worley MJ, Rauh-Hain JA, Sandberg EM, Muto MG. Venous thromboembolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology. Int J Gynecol Cancer 2012; 23:208-15. PubMed
  • May T, Shoni M, Vitonis AF, Quick CM, Growdon WB, Muto MG. The role of para-aortic lymphadenectomy in the surgical staging of women with intermediate and high-risk endometrial adenocarcinomas. Int J Surg Oncol 2013; 2013:858916. PubMed
  • McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 2012; 109:E2939-48. PubMed
  • Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS ONE 2012; 7:e50058. PubMed
  • Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol 2012; 30:387-401. PubMed
  • Young JL, Koon EC, Kwong J, Welch WR, Muto MG, Berkowitz RS, Mok SC. Differential hRad17 expression by histologic subtype of ovarian cancer. 2011; 4:6. PubMed
  • Ordulu Z, Dal Cin P, Chong WW, Choy KW, Lee C, Muto MG, Quade BJ, Morton CC. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer 2010; 49:1152-60. PubMed
  • Folkins AK, Nevadunsky NS, Saleemuddin A, Jarboe EA, Muto MG, Feltmate CM, Crum CP, Hirsch MS. Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. Mod Pathol 2010; 23:1073-9. PubMed
  • Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer 2009; 45:2818-24. PubMed
  • Folkins AK, Saleemuddin A, Garrett LA, Garber JE, Muto MG, Tworoger SS, Crum CP. Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecol Oncol 2009; 115:108-11. PubMed
  • Ko EM,Muto MG,Berkowitz RS,Feltmate CM. Robotic versus open radical hysterectomy: a comparative study at a single institution. Gynecol Oncol 2008; 111:425-30. PubMed
  • Saleemuddin A,Folkins AK,Garrett L,Garber J,Muto MG,Crum CP,Tworoger S. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol 2008; 111:226-32. PubMed
  • Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26:4160-5. PubMed
  • Katagiri A, Fu KI, Sano Y, Ikematsu H, Horimatsu T, Kaneko K, Muto M, Yoshida S. Narrow band imaging with magnifying colonoscopy as a diagnostic tool for predicting the histology of early colorectal neoplasia. Aliment Pharmacol Ther 2008; 27:1269-74. PubMed
  • Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109:168-73. PubMed
  • Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25:3985-90. PubMed
  • Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19:3-9. PubMed
  • Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31:161-9. PubMed
  • Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30:230-6. PubMed
  • Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006; 13:1-7. PubMed
  • Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol 2001; 98:947-50. PubMed
  • Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93:1458-64. PubMed
  • Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, Berkowitz RS, Mok SC, Gershenson DM. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 2001; 61:7264-7. PubMed
  • Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001; 20:244-51. PubMed
  • Huang LW, Garrett AP, Schorge JO, Muto MG, Bell DA, Welch WR, Berkowitz RS, Mok SC. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 2000; 114:93-9. PubMed
  • Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18:2728-32. PubMed
  • Faquin WC, Fitzgerald JT, Lin MC, Boynton KA, Muto MG, Mutter GL. Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues. Am J Clin Pathol 2000; 113:576-82. PubMed
  • Garrett AP, Ng SW, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000; 77:105-11. PubMed
  • Schorge JO, Miller YB, Qi LJ, Muto MG, Welch WR, Berkowitz RS, Mok SC. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000; 76:369-72. PubMed
  • Schorge JO, Muto MG, Lee SJ, Huang LW, Welch WR, Bell DA, Keung EZ, Berkowitz RS, Mok SC. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000; 60:1361-4. PubMed
  • Huang LW, Garrett AP, Muto MG, Colitti CV, Bell DA, Welch WR, Berkowitz RS, Mok SC. Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol 2000; 31:367-73. PubMed
  • Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y.. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19:3-9.
  • Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335:1413-6. PubMed
  • Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996; 56:1250-2. PubMed
  • Muto MG, Kassis AI. Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Cancer 1995; 76:2016-27. PubMed
  • Brown DL, Frates MC, Laing FC, DiSalvo DN, Doubilet PM, Benson CB, Waitzkin ED, Muto MG. Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology 1994; 190:333-6. PubMed
  • Muto MG, Cramer DW, Brown DL, Welch WR, Harlow BL, Xu H, Brucks JP, Tsao SW, Berkowitz RS. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993; 51:12-20. PubMed
  • Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53:1489-92. PubMed
  • Goodman HM, Harlow BL, Sheets EE, Muto MG, Brooks S, Steller M, Knapp RC, Berkowitz RS. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992; 46:367-71. PubMed
  • Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, Bell DA. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 1992; 46:226-9. PubMed
  • Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR, Weadock K, Tumeh SS, Lavin P. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 1992; 45:265-72. PubMed
  • Tsao SW, Mok CH, Oike K, Muto M, Goodman HM, Sheets EE, Berkowitz RS, Knapp RC, Lau CC. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. Anticancer Res 1991; 11:1975-82. PubMed
  • Muto MG, Lage JM, Berkowitz RS, Goldstein DP, Bernstein MR. Gestational trophoblastic disease of the fallopian tube. J Reprod Med 1991; 36:57-60. PubMed
  • Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol 1989; 161:1206-12. PubMed
Hide